ModifiedEmblemHealthPolicy AHS-G2045

Thyroid Disease Testing - Lab Benefit Program (LBM)

Defines coverage criteria, testing frequencies, and limitations for laboratory thyroid function and antibody testing under the Lab Benefit Program for EmblemHealth members.

Policy Summary

PayerEmblemHealth

PolicyThyroid Disease Testing - Lab Benefit Program (LBM)

Policy CodePolicy AHS-G2045

Change TypeCoverage reorganization and monitoring updates

Effective DateMar 1, 2023

Next Review DateN/A

Key ActionWhen TSH is abnormal, obtain reflex fT4 (and fT3/TT3 if TSH low) per the cascade rules and follow updated monitoring intervals (TSH every 6 weeks for hypothyroidism follow-up; every 8 weeks for hyperthyroidism).

SourceLink

POLICY UPDATE CHANGES

Coverage Criteria 1 was edited and divided into multiple criteria to create a cascade approach for TSH vs fT4/fT3/TT3; frequency of testing for TSH retained where appropriate.

New coverage criteria added for follow-up testing after abnormal TSH, monitoring when initial monitoring of fT4 is allowed, and monitoring fT4 without additional TSH for secondary hypothyroidism.

Testing for TBG, TRH, reverse T3, or T3 uptake was edited to never meet coverage criteria.

Coverage Criteria language consolidated so that markers already addressed in the policy are not allowed for other indications (summarized in new CC9).

Removed 'are undergoing evaluation for infertility' from a Coverage Criterion and adjusted related language; added new subcriteria and antibody monitoring rules.

Added CPT code 83520 to the Applicable CPT/HCPCS Procedure Codes table.

Lab Benefit Program (LBM) was expanded to include EmblemHealth HMO/PPO (Non-City) Commercial, Medicare and Medicaid plans effective 10/1/2024.

Frequencies for follow-up changed: hypothyroidism follow-up to every 6 weeks and hyperthyroidism follow-up to every 8 weeks.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

TSH: 1/6 weeksroutine maximum frequency for many indications

TSH: every 3 monthsfrequency for IRT/HIV/transplant

Every 4 weekspregnancy monitoring frequency

TBG/TRH/rT3/T3 uptakeNot covered tests

>15Procedure code list

8+Distinct coverage criteria groups

Coverage Criteria for Thyroid Testing

COVERAGE CRITERIA — Coverage and limitations for thyroid testing

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the 'Applicable State and Federal Regulations' section of this policy document.

ALL of the following

Measurement of thyroid stimulating hormone (TSH) MEETS COVERAGE CRITERIA in any of the following situations.
TSH frequency: no more than one test every six weeks
- For individuals with signs and symptoms consistent with hypothyroidism (see Note 1) or hyperthyroidism (see Note 2).
- For individuals with suspected secondary hypothyroidism.
- For individuals capable of becoming pregnant who have experienced two or more pregnancy losses.
- For individuals with a thyroid nodule.
- For pregnant individuals with a personal history of thyroid dysfunction.
TSH frequency: once every three months
- For individuals undergoing immune reconstitution therapy (IRT), including but not limited to: (i) individuals with active relapsing remitting multiple sclerosis undergoing alemtuzumab (Lemtrada) therapy; (ii) individuals with HIV undergoing highly active antiretroviral therapy (HAART); (iii) individuals following allogeneic bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT).
Once every three months for individuals taking medications known to cause thyrotoxicosis (e.g., amiodarone, interferon-alpha, interleukin-2, lithium, tyrosine kinase inhibitors).
Annual screening indications for TSH
- Individuals with disease or neoplasm of the thyroid or other endocrine glands.
- Individuals with chronic or acute urticaria.
- Pediatric individuals diagnosed with short stature.
- Pediatric individuals with a clinical finding of failure-to-thrive.
- Individuals with type 1 diabetes.

Testing indications and monitoring (guideline-driven) — Guideline statements indicating when testing is recommended or not and monitoring recommendations, especially for pregnancy.

Guideline-driven indications and monitoring recommendations (especially for pregnancy and high-risk populations). These guideline statements inform when testing is recommended and appropriate monitoring intervals.

ALL of the following

USPSTF: Current evidence is insufficient to assess benefits/harms of screening for thyroid dysfunction in nonpregnant, asymptomatic adults; do not screen asymptomatic adults for thyroid cancer.
ACOG (2020) recommendations: universal screening in pregnancy is not recommended; if indicated, measure TSH as first-line; monitor TSH every 4-6 weeks while adjusting levothyroxine in pregnancy with target TSH between lower limit and 2.5 mIU/L; monitor fT4 in pregnant individuals treated for hyperthyroidism with goal fT4 at upper normal pregnancy range; monitor total T3 when T3 thyrotoxicosis present.
ATA/AACE and ATA pregnancy monitoring
- ATA/AACE: Support TSH testing for multiple clinical conditions (e.g., type 1 diabetes, unexplained cardiac dysrhythmia, alopecia, unexplained anemia, weight gain, prolonged QT, vitiligo, etc.).

Coverage-related criteria — Situations where TSH or additional thyroid testing is recommended based on guideline excerpts

Coverage-related follow-up testing and monitoring frequencies, and situations where additional thyroid tests are indicated based on results or clinical context.

ALL of the following

When TSH testing results are abnormal, the following reflex testing MEETS COVERAGE CRITERIA:
ANY of the following
- Free T4 (fT4) as a follow up to abnormal TSH findings.
- Total T3 (TT3) and free T3 (fT3) to confirm a diagnosis of hyperthyroidism when TSH levels are below the normal range.
- fT4 and fT3 for individuals undergoing immune reconstitution therapy (IRT).
Monitoring frequencies that MEET COVERAGE CRITERIA

Summary of coverage stance and major criteria changes — Policy revisions reorganized and clarified into multiple numbered Coverage Criteria (CC1-CC9)

Summary of coverage stance and major operational rules — consolidated coverage criteria and tests that do or do not meet coverage.

ALL of the following

Follow-up and reflex testing that MEET COVERAGE CRITERIA include fT4, fT3/TT3 as specified above; testing frequencies specified in the policy must be applied (e.g., 6-week intervals during dose adjustments, 8-week intervals for hyperthyroidism monitoring during the first year, annual intervals when stable).
Testing for serum thyroglobulin and/or Tg-Ab levels for individuals with thyroid cancer for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas MEETS COVERAGE CRITERIA.
Testing for thyroxine-binding globulin (TBG), thyrotropin-releasing hormone (TRH), reverse T3, or T3 uptake DOES NOT MEET COVERAGE CRITERIA.
For all other situations not mentioned in the policy, testing for any thyroid function markers discussed (e.g., testing for thyroid dysfunction during a general exam without abnormal findings) DOES NOT MEET COVERAGE CRITERIA.

Procedure Codes, Ranges, and Assay Methods

Assay methods (informational)mixed

Assay types described: chemiluminometric assays for TSH; automated competitive binding chemiluminometric assays for total T4/T3; LC/MS/MS referenced for fT4 measurement in pregnancy

Thyroid testing CPT/HCPCSCPT

80438	TRH stimulation panel; 1 hour (includes TSH x3)
80439	TRH stimulation panel; 2 hour (includes TSH x4)
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
84432	Thyroglobulin
84436	Thyroxine; total
84439	Thyroxine; free
84442	Thyroxine-binding globulin (TBG)
84443	Thyroid stimulating hormone (TSH)
84445	Thyroid stimulating immune globulins (TSI)

1–10 of 16

1/2

Thyroid test CPT/HCPCSCPTCovered

80438	TRH stimulation panel; 1 hour (includes TSH x3)
80439	TRH stimulation panel; 2 hour (includes TSH x4)
83520	Immunoassay for analyte, quantitative, not otherwise specified
84443	Thyroid stimulating hormone (TSH)
84439	Thyroxine; free
84436	Thyroxine; total
84480	Triiodothyronine T3; total

Typical lab TSH normal range used by many labs

Typical laboratory reference range~0.4–5.0 mU/L (many laboratories use an upper limit ≈4.5–5.0 mU/L)

Clinical implicationIf serum TSH is normal, no further thyroid testing is routinely needed; abnormal TSH guides reflex testing (high TSH → fT4; low TSH → fT4 and fT3)

Assay sensitivity noteCurrent generation chemiluminometric TSH assays are highly sensitive and detect changes before T4/T3 change

Trimester-specific TSH ranges (ATA)

First trimester0.1–2.5 mIU/L

Second trimester

Provider Actions, Billing, and Monitoring Recommendations

Billing Rule

General reimbursement and coding guidance

Reimbursement Guideline Disclaimer: We have policies in place that reflect billing or claims payment processes unique to our health plans. Current billing and claims payment policies apply to all our products, unless otherwise noted. We will inform you of new policies or changes in policies through postings to the Reimbursement Policies webpage on emblemhealth.com. Further, we may announce additions and changes in our provider manual and/or provider newsletters which are available online and emailed to those with a current and accurate email address on file. The information presented in this policy is accurate and current as of the date of this publication. The information provided in our policies is intended to serve only as a general reference resource for services described and is not intended to address every aspect of a reimbursement situation. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to, legislative mandates, physician or other provider contracts, the member's benefit coverage documents and/or other reimbursement, and medical or drug policies. Finally, this policy may not be implemented the same way on the different electronic claims processing systems in use due to programming or other constraints; however, we strive to minimize these variations. We follow coding edits that are based on industry sources, including, but not limited to, CPT® guidelines from the American Medical Association, specialty organizations, and CMS including NCCI and MUE. In coding scenarios where there appears to be conflicts between sources, we will apply the edits we determine are appropriate. We use industry-standard claims editing software products when making decisions about appropriate claim editing practices. Upon request, we will provide an explanation of how we handle specific coding issues. If appropriate coding/billing guidelines or current reimbursement policies are not followed, we may deny the claim and/or recoup claim payment.

Definitions and Terms

Thyroid disease

DefinitionThyroid disease includes conditions causing hypothyroidism, hyperthyroidism, goiter, thyroiditis, and thyroid tumors.

Clinical scopeEncompasses disorders that alter thyroid hormone production, structure (nodules/tumors), or cause inflammatory dysfunction

Testing purposesUsed to assess thyroid function, monitor treatment, and evaluate suspected thyroid-related symptoms or complications

Acronyms and test terms

Common acronymsTSH, fT4 (FT4), fT3 (FT3), TT4, TT3

Autoantibodies and markersTPOAb, Tg‑Ab, TRAb, TSI, Tg

Other laboratory terms

Policy Revision History

2026-05reorganizationLatest

Policy updated with a major coverage-criteria reorganization effective 2026-09-15: CC1 was divided into multiple criteria to create a cascade approach for TSH versus fT4/fT3/TT3, and new CC2, CC3, and CC4 were added to define follow-up and monitoring rules.

2025-04criteria_revision

Coverage Criteria 1.d was revised to require TSH testing for individuals capable of becoming pregnant who have experienced two or more pregnancy losses; CC1.e was added and Coverage Criteria 4 was reformatted to add specific thyroid antibody testing every three years.

2023-11-13

Policy Summary

PayerEmblemHealth

PolicyThyroid Disease Testing - Lab Benefit Program (LBM)

Policy CodePolicy AHS-G2045

Change TypeCoverage reorganization and monitoring updates

Effective DateMar 1, 2023

Next Review DateN/A

SourceLink

On This Page

ATA (pregnancy): Apply trimester-specific TSH reference ranges (1st: 0.1–2.5 mIU/L; 2nd: 0.2–3.0; 3rd: 0.3–3.0). Use method- and trimester-specific fT4 reference ranges; if unavailable, use best available method (e.g., TT4 with pregnancy-adjusted range or FT4 index).

ATA: Euthyroid and TPO/Tg antibody positive pregnant women should have serum TSH at start of pregnancy and every 4 weeks through mid-pregnancy; monitor every 4 weeks until midgestation and at least once near 30 weeks for those at risk or being treated.

Pregnancy and postpartum specific recommendations

NICE and ATA: Obtain serum TSH early in pregnancy for women with risk factors (history of thyroid dysfunction, symptoms, goiter, TPOAb positivity, age >30, type 1 diabetes, prior miscarriage or preterm delivery, head/neck radiation, family history, morbid obesity, use of amiodarone or lithium, recent iodinated contrast, infertility, residence in iodine-deficient area).
Postpartum Thyroiditis (PPT): Women with postpartum depression should have TSH, fT4, and TPOAb tested; symptomatic women should have TSH retested in 4–8 weeks or be started on LT4 in certain situations; women with history of PPT should have annual TSH to evaluate for permanent hypothyroidism.

ATA: Patients on medications known to cause thyrotoxicosis should be monitored clinically and biochemically at 6-month intervals; patients developing thyrotoxicosis should be evaluated to determine etiology and treated accordingly.

For individuals being treated for primary hypothyroidism: every six weeks when dosages are actively changing; annually in stable individuals.
For individuals being treated for primary hyperthyroidism: every eight weeks for the first year; annual monitoring after the first year.
For individuals with hypothalamic-pituitary disease: biannually for individuals <18 years; annually for individuals ≥18 years.
For individuals diagnosed with primary mitochondrial disease: annual monitoring.
For individuals being treated for secondary hypothyroidism: monitoring of fT4 every six weeks when dosages are actively changing and annually in stable individuals.

NICE and other guidelines: Use cascading testing — consider measuring TSH alone when secondary thyroid dysfunction is not suspected, then measure fT4 if TSH is above reference range, and measure fT4 and fT3 if TSH is below reference range; consider measuring both TSH and fT4 when secondary dysfunction is suspected or in children/young people; repeat testing no sooner than 6 weeks if symptoms worsen.

For children: specific intervals for infants and children per guideline (e.g., under two years: fT4 and TSH every 4–8 weeks until stabilized, then less frequently as noted in guidance).

Apply individual benefit coverage and applicable state/federal regulations when determining coverage. Frequencies and required follow-up depend on clinical context as outlined in the policy and aligned guideline recommendations.

Third trimester0.3–3.0 mIU/L

pregnancy TSH trimester thresholds

Pregnancy TSH thresholds (ATA recommended ranges)1st trimester: 0.1–2.5 mIU/L; 2nd trimester: 0.2–3.0 mIU/L; 3rd trimester: 0.3–3.0 mIU/L

Monitoring frequency noteFor pregnant people with differentiated thyroid cancer and others at risk, monitor TSH approximately every 4 weeks until 16–20 weeks then at least once between 26–32 weeks

Methodology caveatApply trimester-specific reference ranges from populations with optimal iodine intake; serum TSH is the primary indicator in pregnancy

subclinical hyperthyroidism treatment threshold (high-risk)

High‑risk treatment thresholdPersistent TSH < 0.1 mU/L (consider treatment in high‑risk populations such as those >65 years or with cardiac risk factors)

Definition contextSubclinical hyperthyroidism = normal T4/T3 with subnormal TSH; treatment decisions guided by risk status

Diagnostic stepsIf thyrotoxicosis suspected, obtain fT4 and T3 and consider TRAb, radioactive iodine uptake, or thyroid blood flow ultrasound to determine cause

TSH-based cascade testing — If TSH abnormal then measure FT4; if low TSH measure FT4 and FT3 (per guidelines)

Primary cascade ruleMeasure serum TSH first; if TSH is above reference range, measure free T4 in the same sample

Low TSH pathwayIf TSH is below reference range, measure free T4 and free T3 (or TT3) in the same sample to evaluate hyperthyroidism

Secondary/pituitary suspicionIf secondary thyroid dysfunction (pituitary/hypothalamic) suspected, measure both TSH and fT4 concurrently

Note

ACOG pregnancy testing and monitoring actions

The American College of Obstetricians and Gynecologists (ACOG) recommends that universal screening for thyroid disease in pregnancy is not routine. If screening is indicated, measure serum TSH as the first-line test. For pregnant individuals being treated for hypothyroidism, monitor TSH and adjust levothyroxine to achieve a TSH between the lower reference limit and 2.5 mIU/L; TSH is typically evaluated every 4–6 weeks while adjusting therapy. Pregnant individuals with overt hypothyroidism should receive adequate thyroid hormone replacement. For hyperthyroidism in pregnancy, monitor free T4 and adjust antithyroid drugs to achieve a free T4 at the upper end of the normal pregnancy range; for T3 thyrotoxicosis monitor total T3. Treat overt hyperthyroidism with thioamides. Document indication for pregnancy-related testing and monitoring in the medical record to support medical necessity.

Monitor TSH every 4–6 weeks while adjusting levothyroxine in pregnancy.
Use TSH as first-line screening test when indicated in pregnancy.
For hyperthyroidism treatment monitoring, use fT4 (and TT3 where indicated) to guide antithyroid dosing.

Note

Hyperthyroidism diagnostic steps

For suspected thyrotoxicosis or hyperthyroidism, obtain a serum TSH as the initial screening test; if thyrotoxicosis is suspected or TSH is suppressed, also measure free T4 and T3 to assess severity. Consider measurement of thyrotropin receptor antibodies (TRAb), radioactive iodine uptake, or thyroid blood flow on ultrasound to determine etiology when clinically indicated. Treat subclinical hyperthyroidism (persistent TSH <0.1 mIU/L) in high-risk populations (age >65 or cardiac risk factors); consider treatment in symptomatic or other at-risk individuals. In pregnant women with suspected or known hyperthyroidism, test TRAb when etiology is unclear and apply trimester-specific reference ranges for T4 and T3. Ensure documentation of diagnostic rationale and results to support coverage.

Initial testing: TSH first; if abnormal or thyrotoxicosis suspected add fT4 and T3.
Consider TRAb, radioactive iodine uptake, or thyroid Doppler ultrasound to establish cause.
Treat high-risk subclinical hyperthyroidism (TSH <0.1 mIU/L) per guideline recommendations.

Documentation Required

Reimbursement Policy Notice

Follow the Lab Benefit Program (LBM) reimbursement policy for thyroid disease testing. Procedure codes listed in this policy are provided for reference and may not be all-inclusive. Claims that do not follow applicable coding, billing, or documentation requirements may be denied or subject to recoupment. Providers may request an explanation of specific coding edits upon request. Updates to reimbursement policies will be posted on emblemhealth.com and communicated via provider channels.

See Applicable CPT/HCPCS Procedure Codes section for reference codes (policy AHS-G2045).
Noncompliant coding/billing may result in claim denial or recoupment.
Policy updates will be posted to the Reimbursement Policies webpage on emblemhealth.com.

TBG, TRH, reverse T3, T3 uptake; note policy excludes TBG/TRH/reverse T3/T3 uptake from coverage

Pregnancy testing guidance

Trimester-specific ranges requiredLaboratories must use trimester‑specific normal ranges for pregnancy assays; measure hormones only at labs with those ranges

Preferred analytefT4 is the preferred test in pregnancy; use TT4 if fT4 trimester ranges are unavailable or results are discordant

TSH roleSerum TSH remains the primary indicator of thyroid status in pregnancy despite method limitations for fT4 assays

Chemiluminometric assay

Assay typeChemiluminometric assays are current-generation methods for serum TSH measurement

Analytical sensitivityDetection limits approximately 0.01 mU/L, providing improved sensitivity vs older assays (~0.1 mU/L)

Clinical impactHigh analytical sensitivity allows earlier detection of thyroid dysfunction before changes in T4/T3 occur

fT4 measurement by LC/MS/MS

Preferred methodLC/MS/MS measurement of free T4 in dialysate or ultrafiltrate is the best method to assess serum fT4 during pregnancy

If unavailableIf LC/MS/MS is not available, use the next best method and apply method‑specific and trimester‑specific reference ranges

Assay limitationsIndirect analog immunoassays for fT4 can be influenced by pregnancy-related changes—method selection affects interpretation

Trimester-specific TSH ranges

First trimester range0.1–2.5 mIU/L

Second trimester range0.2–3.0 mIU/L

Third trimester range0.3–3.0 mIU/L

Thyroglobulin (Tg) and anti-Tg antibodies (TgAb)

Tg/TgAb in DTC surveillanceMeasure serum thyroglobulin (Tg) with an assay calibrated to BCR457 and quantitatively assess TgAb with every Tg measurement

Monitoring intervalMeasure serum Tg on thyroid hormone therapy every 6–12 months during initial follow‑up; more frequent testing for intermediate/high‑risk patients

Assay limitationsTg immunoassays are affected by TgAb; LC‑MS/MS Tg has low sensitivity and should not be relied on alone when TgAb present

IRT monitoring

Baseline and serial monitoringFor patients undergoing immune reconstitution therapy (e.g., alemtuzumab), obtain baseline TSH and serial TSH monitoring every 3 months for 4 years after last treatment

Reflex testingIf baseline or subsequent TSH abnormal, measure fT4 and fT3 as recommended (suppressed TSH → measure fT4 and fT3)

Antibody testingRoutine measurement of thyroid autoantibodies is not recommended in euthyroid patients prior to IRT

Cascading testing

Cascading approachMeasure TSH first; if abnormal, reflex to FT4 and/or FT3 in the same sample (NICE/ETA recommendations)

Low TSH actionIf TSH below reference range, measure FT4 and FT3 in same sample to evaluate hyperthyroidism

Secondary dysfunctionIf secondary (pituitary) disease suspected, measure both TSH and FT4 concurrently rather than relying on TSH alone

Laboratory-developed test (LDT)

DefinitionLaboratory‑developed tests (LDTs) are laboratory‑validated assays performed in‑house and regulated under CLIA as high‑complexity tests; they are not FDA‑approved for clinical use

Regulatory noteLDTs must be validated by the performing laboratory; FDA clearance/approval is not currently required for clinical use

Reimbursement considerationPolicy acknowledges LDT use and that reimbursement should account for lab‑validated tests

Coverage Criteria (CC#)

Coverage Criteria labelingPolicy uses labeled Coverage Criteria groups (e.g., CC1–CC9) to define when specific thyroid tests meet coverage, follow‑up, monitoring, or exclusion rules

Examples of covered testsTSH as first‑line test, reflex fT4/fT3/TT3 per cascade rules, Tg/TgAb for DTC surveillance

Explicit exclusionsTBG, TRH, reverse T3, and T3 uptake do NOT meet coverage criteria

frequency_update_and_code_changes

Follow-up frequency updated: hypothyroidism follow-up changed to every 6 weeks and hyperthyroidism follow-up changed to every 8 weeks; CPT code 84437 removed and CPT code 84442 added; TBG was added to non-covered tests.